期刊文献+

肝移植术后糖尿病危险因素分析 被引量:6

Risk factors of diabetes mellitus following orthotopic liver transplantation
原文传递
导出
摘要 目的探讨肝移植术后糖尿病(PTDM)的发生及发展的危险因素。方法回顾性分析98例肝移植受者的临床资料。根据其肝移植术后是否发生糖尿病,分为糖尿病组(36例)和非糖尿病组(62例)。以术前和术后可能的9个危险因素作为分析指标,进行这些指标的单因素分析和χ2检验。结果在对两组患者的年龄、乙型肝炎病毒(HBV)感染情况、有无肝硬化及肝硬化的程度、术前糖耐量情况、免疫抑制剂的选择及其血药浓度、激素的使用时间的比较分析中发现:术前肝硬化患者PTDM的发生率明显高于无肝硬化者;肝硬化失代偿期患者PTDM的发生率高于代偿期。术前糖耐量异常的患者PTDM的发生率明显高于糖耐量正常者。激素半年内撤离的患者PTDM的发生率明显低于半年内未撤离者。而两组患者的年龄、HBV的感染情况、免疫抑制剂的选择及其血药浓度相比较,差异均无统计学差异。结论肝硬化、尤其是肝硬化失代偿期,糖耐量异常,长期使用激素是PTDM发生的危险因素。 Objective To study the risk factors of posttransplant diabetes mellitus (PTDM) following orthotopic liver transplantation (OLT). Methods The clinical data of 98 patients undergoing OLT were retrospectively analyzed and the patients were divided into two groups: patients with PTDM (36 cases) and those without PTDM (62 cases). Nine variables were analyzed by χ^2 test. Results Nine variables, including age, HBV infection, cirrhosis, the degree of cirrhosis, glucose tolerance, the choice between CsA and FK506, CsA concentration, FK506 concentration and steroid usage, were analyzed. The variables, including cirrhosis especially decompensation cirrhosis, glucose tolerance and steroid usage, had significant difference between the two groups. The variables, including age, HBV infection, the choice between CsA and FK506, CsA concentration and FK506 concentration, had no significant difference between the two groups. Conclusions Cirrhosis, especially decompensation cirrhosis, abnormal glucose tolerance and long-time steroid usage are risk factors of PTDM following OLT.
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2006年第6期366-368,共3页 Chinese Journal of Organ Transplantation
关键词 肝移植 糖尿病 危险因素 Liver transplantation Diabetes mellitus risk factor
  • 相关文献

参考文献11

  • 1Sato T, Inagaki A, Uchida K, et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation,2003, 76: 1320-1326.
  • 2Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc,2003, 35: 1466-1468.
  • 3Panz VR, Bonegio R, Raal FJ, et al. Diabetogenic effect of tacrolimus in South African patients undergoingkidney transplantation. Transplantation, 2002, 73: 587-590.
  • 4Kruszynska YT, Home PD, Mcintyre N. Relationship between Insulin sensitivity and Glucose Tolerance in cirrhosis. Hepatology, 1991, 14: 103-111.
  • 5Varo E, Padin E, Otero S, et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. Transplant Proc, 2002, 34: 1553-1554.
  • 6Hirano Y, Fujihara S, Ohara K, et al. Morphological and functional changes in islets of Langerhans in FK506-treated rats.Transplantation, 1992, 53: 889.
  • 7Redom JB, Olson LK, Armstrong MB, et al, Effects of trcrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T 15 cells. J Clin Invest,1996, 98: 2786-2793.
  • 8Konrad T, Steinmuller T, Vicini P, et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. Transplantation, 2000, 69:2072-2078.
  • 9Stegall MD, Everson G, Schooter G, et al. Metabolic xomplication after liver transplantation. Transplantation, 1995, 60:1057-1060.
  • 10Mcmahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev, 1988, 4: 17-19.

同被引文献50

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部